SCHEMBL21495028

SCHEMBL21495028

N#CCC(=O)Nc1ncc(-c2cnccn2)s1

nearest known ligand 0.46

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.46
MEN1 O00255 1/20 0.46
ALDH1A1 P00352 1/20 0.46
KMT2A Q03164 1/20 0.46
LIMK1 P53667 10/20 0.44
LIMK2 P53671 10/20 0.44
TESK2 Q96S53 6/20 0.44
TESK1 Q15569 5/20 0.44
CCNE1 P24864 1/20 0.42
CDK2 P24941 1/20 0.42
CDK5 Q00535 1/20 0.42
USP30 Q70CQ3 1/20 0.41
ACP1 P24666 1/20 0.41
PTGS2 P35354 1/20 0.39
PORCN Q9H237 1/20 0.38
ALOX15 P16050 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21484795 0.79 CCNE1 (0.67) KDM4EMEN1ALDH1A1KMT2ACCNE1
SCHEMBL21495022 0.74 ADORA2A (0.50) KDM4EMEN1ALDH1A1KMT2AACP1
SCHEMBL21484796 0.74 ADORA2A (0.55) KDM4EMEN1ALDH1A1KMT2APTGS2
SCHEMBL20353923 0.74 SMN1; SMN2 (0.56) KDM4EMEN1ALDH1A1KMT2A
SCHEMBL21578016 0.74 KDM4E (0.60) KDM4EMEN1ALDH1A1KMT2APTGS2
SCHEMBL28518148 0.72 LIMK1 (0.51) LIMK1LIMK2TESK2TESK1CCNE1
SCHEMBL25682848 0.71 CSNK1D (0.51) LIMK1LIMK2TESK2TESK1CCNE1
SCHEMBL21505742 0.69 CSNK2A1 (0.52) KDM4EMEN1ALDH1A1KMT2AALOX15
SCHEMBL6374561 0.67 ACP1 (0.58) MEN1ALDH1A1KMT2ACDK5ACP1
SCHEMBL21495032 0.67 LIMK1 (0.55) ALDH1A1LIMK1LIMK2TESK2TESK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11584742-B2 Substituted aminothiazoles as inhibitors of nucleases MASARYKOVA UNIVERZITA (CZ) 2023-02-21 US disclosed
US-20220002282-A1 SUBSTITUTED AMINOTHIAZOLES AS INHIBITORS OF NUCLEASES MASARYKOVA UNIVERZITA (CZ) 2022-01-06 US disclosed
CN-112313229-A Substituted aminothiazoles as inhibitors of nucleases 马萨里克大学 2021-02-02 CN disclosed
WO-2019201865-A1 SUBSTITUTED AMINOTHIAZOLES AS INHIBITORS OF NUCLEASES MASARYKOVA UNIVERZITA (CZ) 2019-10-24 WO disclosed
WO-2019201865-A1 SUBSTITUTED AMINOTHIAZOLES AS INHIBITORS OF NUCLEASES MASARYKOVA UNIVERZITA (CZ) 2019-10-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11584742-B2 Substituted aminothiazoles as inhibitors of nucleases RNASEH1, DNASE1, FEN1 KDM4E 1848/4885MEN1 1727/4885ALDH1A1 2267/4885
US-20220002282-A1 SUBSTITUTED AMINOTHIAZOLES AS INHIBITORS OF NUCLEASES RNASEH1, DNASE1, FEN1 KDM4E 1848/4885MEN1 1727/4885ALDH1A1 2267/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.